secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001447362-22-000171
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M
--------------------------------------------------------------------------------

- Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).
- Net loss $(20.2)M vs $(11.8)M; adjusted EBITDA $(8.3)M vs $(5.5)M.
- 2022 revenue guidance raised to $132-137M from $130-135M.
- Three-year target: FY2025 revenue $255-330M; positive net operating cash flow by 2025.
- Acquisitions TissueCypher (690 reports) and IDgenetix (1,208 reports) contributed in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/cstl-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001447362-22-000171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer